| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENSA |
| Uniprot No | O43768 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-121aa |
| 氨基酸序列 | MSQKQEEENPAEETGEEKQDTQEKEGILPERAEEAKLKAKYPSLGQKPGGSDFLMKRLQKGQKYFDSGDYNMAKAKMKNKQLPSAGPDKNLVTGDHIPTPQDLPQRKSSLVTSKLAGGQVE |
| 预测分子量 | 40.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ENSA重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*"Structural basis of PP2A inhibition by ENSA/Arpp19"*
**作者**：Wang et al. (2020)
**摘要**：通过X射线晶体学解析了重组ENSA蛋白与PP2A磷酸酶的复合物结构，揭示了ENSA通过保守的KVF motif结合PP2A-B55亚基并抑制其活性的分子机制，为理解细胞周期调控提供结构基础。
---
2. **文献名称**：*"ENSA regulates sister chromatid cohesion by modulating Wapl activity"*
**作者**：Mochida et al. (2016)
**摘要**：利用重组ENSA蛋白进行体外结合实验，发现其通过拮抗Wapl蛋白调控染色体黏连素(cohesin)稳定性，证明ENSA在有丝分裂早期维持姐妹染色单体黏连中起关键作用。
---
3. **文献名称**：*"A high-throughput assay for ENSA-dependent PP2A inhibition in cancer cells"*
**作者**：García et al. (2018)
**摘要**：开发了一种基于重组ENSA蛋白的荧光筛选平台，用于检测ENSA-PP2A互作在肿瘤细胞中的异常激活，为靶向ENSA的癌症治疗策略提供实验工具。
---
**备注**：以上文献为示例性概括，实际文献需通过数据库(如PubMed/Web of Science)以关键词“ENSA recombinant protein”或“ENSA PP2A”检索获取。
ENSA (Endosulfine Alpha) is a highly conserved eukaryotic protein involved in critical cellular processes, particularly cell cycle regulation. It was initially identified as an endogenous ligand for sulfonylurea receptors but later gained attention for its role in modulating protein phosphatase 2A (PP2A) activity. ENSA functions as a key regulator of the G2/M checkpoint by interacting with the B55 regulatory subunit of PP2A. Under normal conditions, ENSA binds to and inhibits PP2A-B55. allowing cyclin-dependent kinase 1 (CDK1) to remain active for mitotic progression. Upon DNA damage, ENSA is phosphorylated by Greatwall kinase (MASTL), enhancing its inhibitory effect on PP2A-B55 to maintain CDK1 activity and delay mitotic entry for repair. This mechanism is evolutionarily conserved from yeast (where its homolog is Arpp19) to humans.
Structurally, ENSA contains a conserved N-terminal domain critical for PP2A-B55 interaction and disordered regions that facilitate phosphorylation-dependent regulation. Dysregulation of ENSA expression or phosphorylation has been linked to mitotic errors, genomic instability, and diseases including cancer. Overexpression of ENSA correlates with poor prognosis in certain malignancies, likely due to its role in promoting uncontrolled cell division.
Recombinant ENSA proteins are typically produced using bacterial (E. coli) or mammalian expression systems, often with affinity tags (e.g., His-tag) for purification. These engineered proteins enable biochemical studies of PP2A inhibition mechanisms, screening of kinase/phosphatase modulators, and structural analysis of cell cycle regulatory complexes. Recent research also explores ENSA's potential as a therapeutic target, particularly in cancers with defective cell cycle checkpoints. Its unique position at the intersection of CDK1 and PP2A pathways makes it a compelling subject for both basic cell biology and translational oncology studies.
×
